CD8A and non-small cell lung carcinoma: In NSCLC, an immune checkpoint immunoscore calculated on the basis of variables around CD8 and PD-L1 densities and localization was considered as a powerful tool for predicting the efficacy of ICI in patients with NSCLC [57].